Literature DB >> 10886144

Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia.

M Wakugawa1, K Nakamura, H Hino, K Toyama, N Hattori, H Okochi, H Yamada, K Hirai, K Tamaki, M Furue.   

Abstract

BACKGROUND: Bullous pemphigoid (BP) often provokes blood and tissue eosinophilia, which suggests that some chemoattractants modulate the eosinophil infiltration in BP. Eotaxin, a CC chemokine, strongly attracts eosinophils, and interleukin (IL)-5 induces eosinophil differentiation, proliferation and colony formation in vitro.
OBJECTIVES: To examine the correlation between levels of eotaxin and IL-5 and the number of lesional eosinophils, and the expression of eotaxin in BP lesions. PATIENTS/
METHODS: In this study we measured eotaxin and IL-5 levels in blister fluid of BP by enzyme-linked immunosorbent assay. We also examined the expression of eotaxin in BP lesions by immunohistochemistry.
RESULTS: Both eotaxin and IL-5 were detected at high levels in BP blister fluid. Blister fluid eotaxin, but not IL-5 levels, correlated significantly with the number of dermal infiltrating eosinophils. By immunohistochemistry, eotaxin was strongly expressed in epidermal keratinocytes around BP blisters.
CONCLUSIONS: These findings suggest that eotaxin and IL-5 are strongly associated with the tissue eosinophilia of BP. Therapies which aim to inhibit production of eotaxin and IL-5 may improve the inflammation and blister formation in BP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886144     DOI: 10.1046/j.1365-2133.2000.03599.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  25 in total

Review 1.  Autoimmune subepidermal bullous skin diseases: the impact of recent findings for the dermatopathologist.

Authors:  Roberto Verdolini; Rino Cerio
Journal:  Virchows Arch       Date:  2003-06-11       Impact factor: 4.064

Review 2.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

3.  Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid.

Authors:  Kelly N Messingham; Jeffrey W Wang; Heather M Holahan; Rupasree Srikantha; Samantha C Aust; Janet A Fairley
Journal:  Exp Dermatol       Date:  2015-11-23       Impact factor: 3.960

4.  Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells.

Authors:  S Kagami; H Saeki; M Komine; T Kakinuma; Y Tsunemi; K Nakamura; K Sasaki; A Asahina; K Tamaki
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

Review 5.  Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract.

Authors:  Dagmar Simon; Andrew Wardlaw; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2010-04-14       Impact factor: 10.793

6.  Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti.

Authors:  S Jean-Baptiste; E A O'Toole; M Chen; J Guitart; A Paller; L S Chan
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

7.  Interleukin-16 expression and release in bullous pemphigoid.

Authors:  A Frezzolini; G Cianchini; M Ruffelli; S Cadoni; P Puddu; O De Pità
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

Review 8.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 9.  Eosinophils in skin diseases.

Authors:  Susanne Radonjic-Hoesli; Marie-Charlotte Brüggen; Laurence Feldmeyer; Hans-Uwe Simon; Dagmar Simon
Journal:  Semin Immunopathol       Date:  2021-06-07       Impact factor: 9.623

Review 10.  Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.

Authors:  Nina van Beek; Detlef Zillikens; Enno Schmidt
Journal:  Dtsch Arztebl Int       Date:  2021-06-18       Impact factor: 8.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.